81
Pro
0
Against

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

Scientific Claim

Tesamorelin reduces visceral adipose tissue by approximately 18% in HIV-infected patients with central fat accumulation after 12 months of continuous treatment (P < 0.001).

Original Statement

VAT was reduced by approximately 18% (P < 0.001) in patients continuing tesamorelin for 12 months.

From study:Unknown Title

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The study is a randomized controlled trial with a control group, which allows for causal inference. The verb 'reduces' is appropriate for this design.

Evidence from Studies

Supporting (1)

81
81

Unknown Title

Randomized Controlled Trial
Human

This study found that a drug called tesamorelin helped HIV patients lose about 18% of their dangerous belly fat after a year of daily shots, and the results were strong and reliable.

Contradicting (0)

0
No contradicting evidence found